XTalks

MARCH 13, 2024

Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects. Secondly, other funded research is exploring differential gene expression regulated by DNA methylation.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

Find Me Cure

OCTOBER 13, 2019

CDK4/6 inhibitors are used alongside hormone therapy. An enzyme involved in DNA repair can be the key to making chemotherapy more effective. PARP inhibitors work by blocking the function of the PARP enzyme, thus preventing the repair of the tumour DNA. You’ll hear a lot about HER2-targeted therapies but what are they?

Development 52

Development DNA Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 24, 2021

The study will evaluate the efficacy and safety of talazoparib, an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with enzalutamide, an androgen receptor inhibitor, compared with placebo plus enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer (mCSPC).

DNA 52

DNA Clinical Trials Clinical Trials Trials 52

The Pharma Data

AUGUST 5, 2021

When alcohol is metabolized, it breaks down into chemicals which can bind to DNA, resulting in mutations which could become cancerous. Alcohol can also increase the levels of the hormones linked to the development of some types of breast cancer.

Hormones 52

Hormones Research DNA Development 52

Roots Analysis

AUGUST 31, 2023

Gene switches can be regulatory proteins or specific DNA sequences that act to either switch on or off the expression of a gene. Basic Components of Gene Switch Gene switches are composed of noncoding DNA sequences and transcription factors.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

The Pharma Data

MARCH 22, 2021

Radioligand therapy combines a targeting compound that binds to markers expressed by tumors and a radioactive isotope, causing DNA damage that inhibits tumor growth and replication. In metastatic CRPC (mCRPC), the tumor spreads to other parts of the body, such as neighboring organs or bones and remains unresponsive to hormone treatment 4.

Hormones 52

Hormones Gene Therapy Medicine Trials 52

Roots Analysis

SEPTEMBER 9, 2024

Protein expression is a potent technology in the field of synthetic biology, that is utilized for the high-throughput production of proteins as well as enzymes and oligonucleotides (DNA / RNA). This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Contraception : Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

The Pharma Data

AUGUST 17, 2021

Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. About Mismatch Repair Deficiency In normal cells, mismatch repair (MMR) is a process that corrects errors introduced during DNA replication via enzymes. Initiate hormone replacement as clinically indicated.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

APRIL 7, 2023

Inhibition of PARP with Lynparza leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.

Trials 40

Trials DNA Medicine Development 40

The Pharma Data

SEPTEMBER 6, 2021

Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Real world data.

Genome 52

Genome Genomics HR Hormones 52

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Drugs 110

Drugs Licensing Licensing Production 110

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 101

FDA Approval Drugs Sales Development 101

The Pharma Data

OCTOBER 14, 2020

AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH receptor, thereby inducing a prolonged increase in blood calcium levels.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

XTalks

DECEMBER 22, 2021

The gene-editing tool CRISPR edits DNA using specialized strands of guide RNA and endogenous cellular mechanisms of RNA interference. They can provide continuous real-time monitoring of metabolites, bacteria, hormones, glucose and other elements in these fluids. Minimally Invasive Devices.

Life Science 98

Life Science RNA Vaccination Vaccine 98

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Marketing 75

Marketing Production Drugs Licensing 75

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Contraception: Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

OCTOBER 26, 2020

. As monotherapy for the treatment of BRCA 1/2 metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed following a prior therapy that included a new hormonal agent based on the Phase 3 PROfound trial. Final results from this study were recently presented at the ESMO Virtual Congress 2020.

Sales 40

Sales Vaccination Vaccine Production 40

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Alnylam discovers, develops and commercialises drugs based on RNAi interference.

Antibody 130

Antibody Hormones DNA Genome 130

The Pharma Data

JANUARY 21, 2021

The test valuates mitochondrial DNA levels. When mitochondrial DNA, normally found inside cells, in the mitochondria, spills into the bloodstream, it signals that a particular type of violent cell death is occurring. They measured the patients’ mitochondrial DNA levels on the first day of their hospital stays.

Research 52

Research DNA Hormones Vaccine 52

XTalks

FEBRUARY 27, 2025

SERENA-6 is unique as the first global, double-blind study to use circulating tumor DNA (ctDNA) monitoring a blood-based approach to detect early signs of endocrine resistance. By tracking small fragments of tumor DNA in the bloodstream, researchers identified the emergence of ESR1 mutations before clinical progression appeared.

Trials 59

Trials HR Clinical Trials Clinical Trials 59